AbbVie Inc (ABBV)vsAmylyx Pharmaceuticals Inc (AMLX)
ABBV
AbbVie Inc
$234.89
+0.06%
HEALTHCARE · Cap: $391.50B
AMLX
Amylyx Pharmaceuticals Inc
$16.28
-6.92%
HEALTHCARE · Cap: $1.69B
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates -9446566% more annual revenue ($62.82B vs $-665,000). ABBV leads profitability with a 5.8% profit margin vs 0.0%. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
AMLX
Avoid31
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-48.1%
Fair Value
$146.22
Current Price
$234.89
$88.67 premium
Intrinsic value data unavailable for AMLX.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 32.2%
Conservative balance sheet, low leverage
Growing faster than its price suggests
Generating 3.6B in free cash flow
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Areas to Watch
5.8% margin — thin
Premium valuation, high expectations priced in
Earnings declined 46.2%
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Operating margin of 0.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 12.4% demonstrates continued momentum. PEG of 0.61 suggests the stock is reasonably priced for its growth.
Bull Case : AMLX
The strongest argument for AMLX centers on Debt/Equity, Altman Z-Score.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 108.6x leaves little room for execution misses.
Bear Case : AMLX
The primary concerns for AMLX are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
ABBV carries more volatility with a beta of 0.31 — expect wider price swings.
ABBV is growing revenue faster at 12.4% — sustainability is the question.
ABBV generates stronger free cash flow (3.6B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ABBV scores higher overall (63/100 vs 31/100) and 12.4% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Amylyx Pharmaceuticals Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Amylyx Pharmaceuticals Inc (AMLX) is a pioneering biopharmaceutical company dedicated to creating transformative therapies for neurodegenerative diseases, with a primary focus on amyotrophic lateral sclerosis (ALS). The company’s lead product candidate, AMX0035, features an innovative neuroprotective mechanism that has demonstrated promising results in enhancing patient outcomes. Backed by a strong clinical pipeline and a team of specialists in neurology, Amylyx is strategically positioned to address critical unmet medical needs, presenting a compelling investment opportunity for institutional investors interested in cutting-edge solutions for challenging neurological disorders.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?